Related Experiment Video
Updated: Jun 8, 2026
08:16
Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
Published on: June 17, 2015
Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation
Francisco J Gil-Bea1, Maite Solas, Laura Mateos
1Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center, Karolinska Institutet, Stockholm, Sweden. Francisco.Gil-Bea@ki.se
Hippocampus
|September 25, 2010
Summary
Hippocampal cholinergic denervation impairs spatial memory by reducing activity-regulated cytoskeleton associated protein (Arc) and brain-derived neurotrophic factor (BDNF). Galantamine treatment reversed these deficits, highlighting muscarinic receptor roles in memory.
Area of Science:
- Neuroscience
- Molecular Biology
- Behavioral Neuroscience
Background:
- Activity-regulated cytoskeleton associated protein (Arc) and brain-derived neurotrophic factor (BDNF) are crucial for synaptic plasticity and memory consolidation.
- Cholinergic deafferentiation of the hippocampus is known to cause memory impairments, but the underlying mechanisms are not fully understood.
Purpose of the Study:
- To investigate the role of hippocampal cholinergic denervation in spatial memory acquisition and synaptic consolidation.
- To analyze the impact of cholinergic deficits on Arc and BDNF levels in the hippocampus.
- To explore the therapeutic potential of galantamine in reversing these memory impairments.
Main Methods:
- Induction of cholinergic hypofunction using (192) IgG-saporin toxin in rats.
- Assessment of spatial memory acquisition using the Morris water maze (MWM).
- Quantification of Arc and BDNF protein and mRNA levels in hippocampal tissue.
- In vitro stimulation of hippocampal primary neurons to examine receptor-specific effects on Arc production.
Main Results:
- Cholinergic denervation significantly decreased hippocampal Arc and BDNF levels.
- Lesioned rats exhibited impaired spatial memory acquisition in the MWM.
- Galantamine treatment reversed memory deficits and normalized Arc and BDNF levels.
- Muscarinic receptor stimulation, but not nicotinic, induced Arc production in hippocampal neurons.
Conclusions:
- Hippocampal cholinergic denervation impairs spatial memory acquisition through reduced muscarinic-dependent induction of Arc.
- Arc and BDNF are key molecular players in the observed memory deficits.
- Galantamine shows potential for treating cholinergic-induced memory impairments by restoring Arc and BDNF levels.
Related Concept Videos
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...